Eliot Ward - Oct 04, 2023

UPC at four months old - a review

The UPC is now four months old and the Court of First Instance is..

Maria Hall - Sep 19, 2023

Mewburn Ellis praised for achievements in sustainability

EcoVadis ratings highlight environmental policies and sustainable..

Jacqueline Murphy - Mar 07, 2023

Come and join us for a ‘Celebration of all things Singapore’

We are excited to be in Singapore for INTA 2023 and very much hope..

Richard Clegg - Jan 18, 2023

Opting out from the UPC – when to opt-out a pending European patent application

From 1 March 2023, when the Unified Patent Court (UPC) sunrise period..

Jacqueline Murphy - Sep 30, 2021

Mewburn Ellis: top tier firm Legal 500 2022

Mewburn Ellis is proud to be ranked top tier for our patent and trade..

Richard Clegg - Aug 06, 2021

Mewburn Ellis board signs IP Inclusive Leaders’ Pledge

Mewburn Ellis’ nine board members are proud to be amongst dozens of..

Richard Clegg - Nov 19, 2020

Diversity & inclusion is high on our agenda

Diversity & inclusion is high on the agenda for Mewburn Ellis, it’s..

Richard Clegg - May 14, 2020

Singapore's biotech breakthrough

From the far east to the east coast of America, the world is taking..

Richard Clegg - Mar 20, 2020

Changes to our correspondence address

In response to the current situation in London due to Coronavirus..

Richard Clegg - Mar 03, 2020

Coronavirus (COVID-19) Update

Updated: 2pm Sunday 1st November 2020

Mewburn Ellis took the..

Richard Clegg - Feb 12, 2020

Oppositions & Appeals: we opened the door for different types of data to support a medical use 

Case 4 - T 801/06 (EPO Board of Appeal, 4 March 2009)

Now cited in..

Richard Clegg - Nov 15, 2019

Meet the team: Richard Clegg, Partner, European Patent Attorney, Patent Attorney Litigator

As part of our 'meet the team' series, we talk to Richard Clegg about..

Richard Clegg - Aug 13, 2019

Challenges Post­ Selex

Twenty-five years ago Tuerk and Gold reported the Selex method. Being..

Richard Clegg - Dec 10, 2018

Clovis Oncology success in European Opposition Proceedings related to Rubraca®

Clovis Oncology has announced that the European Patent Office (EPO)..

Richard Clegg - Oct 31, 2018

Morphosis: creating and nurturing biotech start-ups in Singapore

We understand that early-stage biotech companies do not have it easy...